Medpace Holdings Inc
$ 514.90
-2.56%
21 Apr - close price
- Market Cap 15,091,210,000 USD
- Current Price $ 514.90
- High / Low $ 530.07 / 511.38
- Stock P/E 34.61
- Book Value 16.18
- EPS 15.27
- Next Earning Report 2026-04-22
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.16 %
- ROE 0.70 %
- 52 Week High 628.92
- 52 Week Low 282.84
About
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Analyst Target Price
$500.08
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-09 | 2025-10-22 | 2025-07-21 | 2025-04-21 | 2025-02-10 | 2024-10-21 | 2024-07-22 | 2024-04-22 | 2024-02-12 | 2023-10-23 | 2023-07-24 | 2023-04-24 |
| Reported EPS | 4.67 | 3.86 | 3.103 | 3.67 | 3.6813 | 3.01 | 2.75 | 3.2 | 2.46 | 2.22 | 1.93 | 2.27 |
| Estimated EPS | 4.18 | 3.53 | 2.99 | 3.0775 | 3.1167 | 2.78 | 2.54 | 2.47 | 2.22 | 2.05 | 1.91 | 1.8 |
| Surprise | 0.49 | 0.33 | 0.113 | 0.5925 | 0.5646 | 0.23 | 0.21 | 0.73 | 0.24 | 0.17 | 0.02 | 0.47 |
| Surprise Percentage | 11.7225% | 9.3484% | 3.7793% | 19.2526% | 18.1153% | 8.2734% | 8.2677% | 29.5547% | 10.8108% | 8.2927% | 1.0471% | 26.1111% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-22 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 3.74 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MEDP
2026-04-21 16:10:05
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Medpace Holdings, Inc. (NASDAQ: MEDP) on behalf of investors who purchased securities between April 22, 2025, and February 9, 2026. The lawsuit alleges that Medpace made materially false and misleading statements regarding its expected book-to-bill ratio. Investors are encouraged to join the case by June 5, 2026, to potentially recover damages.
2026-04-21 15:10:05
The Schall Law Firm is encouraging investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) securities between April 22, 2025, and February 9, 2026, to join a class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements to the market, artificially inflating its share price, which resulted in investor damages. Investors have until June 5, 2026, to contact the firm to participate.
2026-04-21 13:16:00
Faruqi & Faruqi, LLP has reminded Medpace (MEDP) investors of the June 8, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rate and provided overly positive growth expectations. This led to a significant stock price drop after the company announced a book-to-bill ratio of 1.04, below its guidance of 1.15.
2026-04-21 03:10:05
Medpace Holdings (MEDP) is set to release its Q1 earnings, with analysts expecting a 24.7% year-over-year revenue growth. The company previously exceeded revenue expectations in the last quarter, reporting $708.5 million, marking a 32% increase. Despite Medpace missing Wall Street's revenue estimates multiple times in the past two years, there's positive investor sentiment in the life sciences tools & services sector, with Medpace's shares up 15.7% in the last month.
2026-04-21 00:09:51
Robbins LLP is urging investors who lost money in Medpace Holdings Inc. (NASDAQ: MEDP) to contact the firm regarding a class action lawsuit. The lawsuit alleges that Medpace misled investors by providing an overly optimistic expected book-to-bill ratio of 1.15 for Q4 2025, while the actual ratio announced on February 9, 2026, was 1.04, causing a significant stock price decline. Shareholders who wish to serve as lead plaintiff must submit papers by June 8, 2026.
2026-04-20 20:09:51
Levi & Korsinsky, LLP has issued an investor alert regarding a securities class action lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP), naming senior executives as individual defendants. The lawsuit alleges that the company's Q4 2025 book-to-bill ratio of 1.04 was significantly lower than the projected 1.15, leading to a substantial drop in share price. Investors who suffered losses during the class period of April 22, 2025, through February 9, 2026, have until June 8, 2026, to apply for lead plaintiff status.
